Nyrada Inc - Annual Report 2021

Annual Report FY21 27 Short-term employee benefits Post- employment benefits Share- based payments Salary & fees Bonus Other Super- annuation Options 3 Total 2020 $ $ $ $ $ $ Non-Executive Directors John Moore 63,340 - - - 157,168 220,508 Graham Kelly 1 266,628 - - 21,937 250,215 538,780 Peter Marks 51,220 - - - 138,719 189,939 Marcus Frampton 24,519 - - - 78,584 103,103 Rüdiger Weseloh 20,432 - - - 78,584 99,016 Christopher Cox 2 24,519 - - - 78,584 103,103 Executive Employees James Bonnar (CEO) 275,000 - - 26,125 1,213 302,338 Total 725,658 - - 48,062 783,067 1,556,787 1 Graham Kelly was an employee for the period 1 July 2019 to 18 November 2019. On 18 November 2019, Dr. Kelly entered into a Consulting Agreement to provide strategic and advisory consulting services for the Company. The Consulting Agreement ceased on 31 March 2020 when Dr. Kelly transitioned to a Non-Executive Director. 2 Christopher Cox was appointed as Director on 7 November 2019. 3 The value included in the share-based payment options column is calculated using sophisticated financial models. The expense is apportioned from the grant date to the date the options vest. As at the date of this report, no KMP options have been exercised and this amount does not represent a cash benefit to the KMP. Other transactions with Key Management Personnel and their related parties Prue Kelly, spouse of Graham Kelly (Non-Executive Director) was employed as the Company's part-time Executive Assistant and Investor Relations Manager on the Company's employment terms and conditions. Refer to note 20 to the financial statements for further details. During the year the Company fully settled a $342,322 loan to related party, Noxopharm Ltd. The loan was repayable upon the March 2021 Placement. The facility was unsecured with no interest payable.